1,3,5-Triazin-2(1H)-one, 4-amino-1-(2-deoxy-4-thio-β-D-erythro-pentofuranosyl)- manufacturers
|
| | 1,3,5-Triazin-2(1H)-one, 4-amino-1-(2-deoxy-4-thio-β-D-erythro-pentofuranosyl)- Basic information |
| | 1,3,5-Triazin-2(1H)-one, 4-amino-1-(2-deoxy-4-thio-β-D-erythro-pentofuranosyl)- Chemical Properties |
| Boiling point | 495.4±55.0 °C(Predicted) | | density | 1.91±0.1 g/cm3(Predicted) | | pka | 13.95±0.60(Predicted) | | form | Solid | | color | White to off-white |
| | 1,3,5-Triazin-2(1H)-one, 4-amino-1-(2-deoxy-4-thio-β-D-erythro-pentofuranosyl)- Usage And Synthesis |
| Uses | 2'-Deoxy-4'-thio-5-azacytidine-15N4 is an isotopic labelled compound of 2'-Deoxy-4'-thio-5-azacytidine (D211885). 2'-Deoxy-4'-thio-5-azacytidine is used in the preparation of 5-azacytosine nucleosides with potential anticancer properties. | | in vivo | 5-Aza-4'-thio-2'-deoxycytidine (6.7, 10 mg/kg/day; IP; for 9 days) is effective against NCI-H23 tumor xenografts[1].
5-Aza-4'-thio-2'-deoxycytidine (5 mg/kg/day; IP; for 9 days) decreases DNMT1 levels in tumors of CCRF-CEM tumors mice xenografts[1].
5-Aza-4'-thio-2'-deoxycytidine (1.5 mg/kg; ip; QD×5 rest and repeat 3 cycles) provides modest suppression of tumor growth as well in the HCT116 colon carcinoma, OVCAR3 ovarian tumor xenograft model. 5-Aza-4'-thio-2'-deoxycytidine has minimal antitumor effect in the HL-60 leukemia xenografts[2].
| Animal Model: | Young female athymic nu/nu mice with NCI-H23 tumor fragment[1] | | Dosage: | 6.7 or 10 mg/kg | | Administration: | IP; daily for 9 days | | Result: | Had antitumor efficacy against NCI-H23 tumor xenografts.
|
| | IC 50 | DNMT1 |
| | 1,3,5-Triazin-2(1H)-one, 4-amino-1-(2-deoxy-4-thio-β-D-erythro-pentofuranosyl)- Preparation Products And Raw materials |
|